Intention-to-Treat (ITT)

Intention-to-Treat (ITT) - Axcellant

Intention-to-Treat (ITT)

  1. lut 28, 2025

What Does the 'Intention-to-Treat (ITT)’ Mean?

Intention-to-Treat (ITT) is a principle used in the design and analysis of randomized controlled trials. It refers to the practice of analyzing all participants in the groups to which they were originally randomly assigned, regardless of whether they actually received the intended treatment or completed the study.

The ITT approach helps maintain the balance of baseline characteristics between treatment groups achieved through randomization. It also provides a more conservative estimate of treatment effect by including all randomized participants, which better reflects real-world scenarios where patients may not always adhere to prescribed treatments.

Why Is the 'Intention-to-Treat (ITT)’ Important in Clinical Research?

Intention-to-Treat (ITT) is crucial in clinical research as it helps maintain the integrity of randomization and minimizes bias in treatment effect estimates. By analyzing all randomized participants, regardless of protocol deviations, ITT provides a more realistic assessment of treatment effectiveness in real-world settings where perfect adherence is rare.

ITT analysis is also important for regulatory purposes and is often required by agencies like the FDA for pivotal clinical trials. It helps prevent overestimation of treatment effects that can occur when only compliant participants are analyzed, thus providing a more conservative and reliable basis for healthcare decision-making.

Good Practices and Procedures

  1. Clearly define ITT population in the study protocol, specifying how missing data and protocol deviations will be handled
  2. Implement strategies to minimize participant dropout and maximize treatment adherence
  3. Use appropriate statistical methods, such as multiple imputation, to handle missing data in ITT analyses
  4. Conduct sensitivity analyses to assess the impact of different assumptions about missing data on study conclusions
  5. Report both ITT and per-protocol analyses, explaining any discrepancies between the two approaches

Related Terms

Resources

Axcellant Establishes Advisory Board to Strengthen Clinical and Strategic Leadership

Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…

One trial is no longer enough. Regulators on both sides of the Atlantic are building a new model of clinical evidence

The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…

Imaging Core Lab in Nuclear Medicine: Standardization, Quality Control, and Regulatory Alignment in Clinical Trials 

Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…